Discrepant alterations in main candidate genes among multiple primary melanomas
- PMID: 24885594
- PMCID: PMC4023698
- DOI: 10.1186/1479-5876-12-117
Discrepant alterations in main candidate genes among multiple primary melanomas
Abstract
Background: Alterations in key-regulator genes of disease pathogenesis (BRAF, cKIT, CyclinD1) have been evaluated in patients with multiple primary melanoma (MPM).
Methods: One hundred twelve MPM patients (96 cases with two primary melanomas, 15 with three, and 1 with four) were included into the study. Paired synchronous/asynchronous MPM tissues (N=229) were analyzed for BRAF mutations and cKIT/CyclynD1 gene amplifications.
Results: BRAF mutations were identified in 109/229 (48%) primary melanomas, whereas cKIT and CyclinD1 amplifications were observed in 10/216 (5%) and 29/214 (14%) tumor tissues, respectively. While frequency rates of BRAF mutations were quite identical across the different MPM lesions, a significant increase of cKIT (p<0.001) and CyclinD1 (p=0.002) amplification rates was observed between first and subsequent primary melanomas. Among the 107 patients with paired melanoma samples, 53 (49.5%) presented consistent alteration patterns between first and subsequent primary tumors. About one third (40/122; 32.8%) of subsequent melanomas presented a discrepant pattern of BRAF mutations as compared to incident primary tumors.
Conclusions: The low consistency in somatic mutation patterns among MPM lesions from same patients provides further evidence that melanomagenesis is heterogeneous and different cell types may be involved. This may have implications in clinical practice due to the difficulties in molecularly classifying patients with discrepant primary melanomas.
Figures
Similar articles
-
Oncogene abnormalities in a series of primary melanomas of the sinonasal tract: NRAS mutations and cyclin D1 amplification are more frequent than KIT or BRAF mutations.Hum Pathol. 2013 Sep;44(9):1902-11. doi: 10.1016/j.humpath.2013.01.025. Epub 2013 May 9. Hum Pathol. 2013. PMID: 23664541 Free PMC article.
-
[Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].Magy Onkol. 2013 Jun;57(2):96-9. Epub 2013 May 20. Magy Onkol. 2013. PMID: 23795354 Hungarian.
-
BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.J Clin Oncol. 2012 Jul 10;30(20):2522-9. doi: 10.1200/JCO.2011.41.2452. Epub 2012 May 21. J Clin Oncol. 2012. PMID: 22614978
-
Molecular pathogenesis of malignant melanoma: a different perspective from the studies of melanocytic nevus and acral melanoma.Pigment Cell Melanoma Res. 2010 Feb;23(1):64-71. doi: 10.1111/j.1755-148X.2009.00645.x. Epub 2009 Sep 25. Pigment Cell Melanoma Res. 2010. PMID: 19788535 Review.
-
Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations.Future Oncol. 2013 Feb;9(2):245-53. doi: 10.2217/fon.12.179. Future Oncol. 2013. PMID: 23414474 Review.
Cited by
-
Epidemiological and genetic factors underlying melanoma development in Italy.Melanoma Manag. 2015 May;2(2):149-163. doi: 10.2217/mmt.15.12. Epub 2015 May 18. Melanoma Manag. 2015. PMID: 30190844 Free PMC article. Review.
-
Heterogeneity and frequency of BRAF mutations in primary melanoma: Comparison between molecular methods and immunohistochemistry.Oncotarget. 2017 Jan 31;8(5):8069-8082. doi: 10.18632/oncotarget.14094. Oncotarget. 2017. PMID: 28039443 Free PMC article.
-
Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets.Front Oncol. 2015 Aug 10;5:183. doi: 10.3389/fonc.2015.00183. eCollection 2015. Front Oncol. 2015. PMID: 26322273 Free PMC article. Review.
-
Lysosomal acid ceramidase ASAH1 controls the transition between invasive and proliferative phenotype in melanoma cells.Oncogene. 2019 Feb;38(8):1282-1295. doi: 10.1038/s41388-018-0500-0. Epub 2018 Sep 25. Oncogene. 2019. PMID: 30254208
-
Association of homogeneous inflamed gene signature with a better outcome in patients with metastatic melanoma treated with MAGE-A3 immunotherapeutic.ESMO Open. 2018 Jul 25;3(5):e000384. doi: 10.1136/esmoopen-2018-000384. eCollection 2018. ESMO Open. 2018. PMID: 30094070 Free PMC article.
References
-
- Dummer R, Hauschild A, Guggenheim M, Keilholz U, Pentheroudakis G. ESMO Guidelines Working Group: Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii86–vii91. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials